期刊文献+

奥美拉唑肠溶胶囊的生物等效性研究 被引量:5

Bioequivalence of omeprazole enteric capsule
下载PDF
导出
摘要 目的:研究奥美拉唑肠溶胶囊在健康人体的药代动力学,并评价其与同剂量制剂间的生物等效性。方法:采用双交叉试验设计,18名健康志愿者口服奥美拉唑肠溶胶囊试验和参比制剂40mg,服药后0~12h内间隔取血,用HPLC法测定血药浓度。计算主要药代动力学参数,并以参比制剂计算奥美拉唑肠溶胶囊的相对生物利用度,判断其生物等效性。结果:奥美拉唑肠溶胶囊试验和参比制剂的体内药代动力学参数Cmax(0.632±0.383)mg/L和(0.626±0.415)mg/L、5Tmax(2.39±0.40)h和(2.33±0.42)h、T1,2(1.92±0.64)h和(2.01±0.73)h、Vd/F(81.21±46.68)L和(94.07±89.46)L、CL/F(32.99±20.92)L/h和(31.68±20.41)L/h、AUC0→12(2.03±1.99)mg/(h·L)^1-和(1.89±1.62)mg/(h·L)^-1;受试奥美拉唑肠溶胶囊的相对生物利用度F=(104.7±17.7)%。结论:2种制剂具有生物等效性。 Objective: To evaluate the pharmacokinetics and bioequivalence of omeprazole enteric capsule in heslthy Chinese. Methods: Randomized cross -over design was adopted, 18 healthy subjects took omeprazole enteric capsule and reference preparation 40 mg orally in one time. Serial blood samples were collected at scheduled intervals during 12 h. The samples were analyzed for omeprazole and reference preparation concentration in plasma by HPLC. The main pharmacokinetics parameters of the omeprazole and reference preparation were Calculated and analyzed. Results: The main pharmacokinetic parameters in test and reference preparation were following accordingly: Tmax were 2.39 ±0.40 and 2.33 ±0.42 h ; Cmax were 0. 632 ±0. 383 and 0. 626 ±0. 415 mg/L; T1/2 were 1.92 ±0.64 and 2.01 ±0.73 h ; Vd/F were 81.21 ±46.68 and 94.07 ±89.46 L; CL/F were 32.99 ± 20.92 and 31.68 ± 20.41 L/h; AUC0→12 were 2.03 ± 1.99 and 1.89 ± 1.62 mg/(h ·L)^-1. The relative bioavailability of omeprazole was 104.7 ± 17.7%. Conclusion: The two omeprazole preparations are bioequivalent.
出处 《海南医学院学报》 CAS 2008年第2期110-112,115,共4页 Journal of Hainan Medical University
关键词 奥美拉唑 药代动力学 色谱法 高效液相 Omeprazole Pharmacokinetics Chromatography, high performance liquid (HPLC)
  • 相关文献

参考文献5

二级参考文献22

  • 1楼雅卿,赵莉,张远.中国健康志愿者的奥美拉唑及其代谢物的药代动力学研究[J].中国临床药理学杂志,1994,10(1):14-21. 被引量:27
  • 2邓子煜,李雪宁,陈秋潮.HPLC测定奥美拉唑血药浓度[J].中国药学杂志,1996,31(10):608-610. 被引量:14
  • 3[1]de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans[J]. J Biol Chem, 1994, 269(22):15419-15422.
  • 4[2]Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study[J]. Clin Pharmacol Ther, 1995, 57(6):662-669.
  • 5[3]Garcia-Encina G, Farran R, Puig S, Martinez L. Validation of an automated liquid chromatographic method for omeprazole in human plasma using on-line solid-phase extraction[J]. J Pharm Biomed Anal, 1999, 21(2):371-382.
  • 6[4]Fu LQ,Huang F, Wu DZ, Guo JH. The plasma concentration of omeprazole and metabolites 5′-hydroxyomeprazole, omeprazole sulphone are determinated by HPLC[J]. Chin Pharmacol Bull(中国药理学通报), 2002, 18(3):342-344.
  • 7[5]Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19[J]. Br J Clin Pharmacol, 1995, 39(5):511-518.
  • 8[6]Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. Pharmacokinetics and bioavai- lability of omeprazole after single and repeated oral administration in healthy subjects[J]. Br J Clin Pharmacol, 1990, 29(5):557-563.
  • 9[7]Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators[J]. Ther Drug Monit, 1990, 12(4):415-416.
  • 10[8]Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population[J]. J Pharmacol Exp Ther, 1992, 262(3):1195-1202.

共引文献57

同被引文献46

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部